[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
September 2003

Scoring With SCORTEN

Author Affiliations

Not Available

Arch Dermatol. 2003;139(9):1215. doi:10.1001/archderm.139.9.1215-a

We were interested to read the series of articles on the efficacy of intravenous immunoglobulin (IVIG) for the treatment of toxic epidermal necrolysis (TEN), published in the January issue of ARCHIVES. Most reports of trials of therapy in TEN are case series with no control group and so are difficult to interpret. The articles by Trent et al1 and Bachot et al2 address this by comparing actual mortality of IVIG-treated patients with mortality predicted by the SCORTEN prognostic scoring index.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×